Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain discusses the importance of identifying frail/elderly patients using well-establish tools, such as geriatric scales (clinical frailty scales). Dr Mateos also dicusses the available treatment options for this population, such as oral combinations with checkpoint inhibitors and monoclonal antibodies. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
Author: Editor
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the highlights in the field of multiple myeloma (MM), presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Prof. Landgren focuses on 3 drugs approved by the US Food and Drug Administration (FDA) in November, 2015, two monoclonal antibodies (daratumumab and elotuzumab), and the oral proteosome inhibitor ixazomib. Prof. Landgren also talks about the many combination therapies being presented at ASH 2015, involving three drugs allowing for longer progression free survival (PFS) and overall survival (OS) in MM patients. Another…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about biomarkers of cardiotoxicity in multiple myeloma in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about cardio-oncology in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Institut Gustave Roussy, Villejuif, France, summarises the recent progress in the management of patients with castration-resistant prostate cancer. In addition to an improvement in patient care, there have been improvements in imaging procedures as well as the pathological and molecular understanding of prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint inhibitors at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm for metastatic CRC at ASCO 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers at ASCO Gi 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses mutational load of colorectal and non-colorectal cancers may benefit significantly from immunotherapy.at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1 blockade at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses the MAVERICC Phase II study results at ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor in advanced CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 Adverse events compared to other approved flouropyrmidines at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from TAS-102 at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses the primary and secondary endpoints of the RECOURSE trial for which TAS-102 was approved at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment of mCRC patients at ASCO GI 2016
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses phase 3 clinical trials of atezolizumab, an anti-PD-L1 monoclonal antibody, compared with standard chemotherapy in PD-L1-selected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from LUX-lung 7, a randomised, open-label, phase 2b trial comparing afatinib to gefitinib in the first-line treatment setting with patients who are having epidermal growth factor receptor (EGFR) mutation-positive advanced adenocarcinoma of the lung. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from KEYNOTE-010, a phase 2/3 study of pembrolizumab, anti-PD-1 antibody, versus docetaxel for patients with PD-L1-positive non-small cell lung cancer (NSCLC) who had disease progression after platinum-containing systemic therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the clinical development of AZD9291, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M-mutant non-small cell lung cancer (NSCLC) following resistance to frontline anti-EGFR therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL, and how these impact the treatment landscape in chronic lymphocytic leukemia (CLL).
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses associated with long-term therapies in chronica lymphocytic leukemia (CLL). At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, data on several new therapies was presented, which indicates a new era for CLL, where patients will be treated for longer periods of time, potentially lasting several years. This raises financial and political issues that are being discussed in the CLL community, with clinicians and advocates pushing for the development of finite therapies that can achieve complete remission or minimum residual disease (MRD) negativity.
Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies being presented at the America Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Prof. Hallek discusses the new data being presented on venetoclax (ABT-199), a Bcl-2 inhibitor, in CLL patient with 17p deletion or mutated p53, and inhibitors targeting well-known CLL targets, such as Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), as single-agents or in combinations with other therapies.
Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical trial, a Phase III study for untreated diffuse large B-cell lymphoma patients. The aims of this study were to compare R-CHOP plus bortezomib to R-CHOP alone, as front-line therapy. The trial also aimed to develop a gene expression profiling test to determine the genetic sub-type (ABC or GCB), and if the different sub-types would have an increased benefit from the addition of bortezomib therapy.
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the results to date of LUX-Lung 7, a global, randomised, open-label, phase 2b clinical trial comparing afatinib, an irreversible ErbB family blocker, to gefitinib for the first-line treatment of patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the application of the concept oncogene addiction, which postulates that a cancer cell exhibits dependence on a single oncogenic pathway or protein for its sustained proliferation or survival, in the development of targeted therapies for non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal cancer at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses the NEOSCOPE trial results and management of resectable esophageal adenocarcinoma at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses why the NEOSCOPE trial may not be significantly and clinically meaningful at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced gastric adenocarcinoma at ASCO GI 2016
The Role of PD-L1 Pathway in Cancer Immune Invasion
The Importance of PD-L1 Expressions on Tumor and Immune Cells
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London, UK, discusses the aims of his research group, which include understanding the genes involved in tumour evolution and developing “molecular archaeology” approaches that use genomic information to create detailed timelines of cancer development across many different cancer types. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Howard S Hochster, MD of Yale Medical Center discusses adverse event profile for TAS-102 at ASCO GI 2016
Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer at ASCO GI 2016
Howard S Hochster, MD of Yale Medical Center discusses Phase III RECOURSE trial on which FDA approval for TAS-102 was based at ASCO Gi 2016
Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO GI 2016
Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1 at ASCO GI 2016
Davendra Sohal, MD of Cleveland Clinic discusses the reason microsatellite instability responds to immunotherapy in colon cancer at ASCO GI 2016